Helper innate lymphoid cells as cell therapy for cancer.
adoptive cell therapy
antitumour immune response
cancer
cell therapy
immunotherapy
innate lymphoid cells
Journal
Immunology
ISSN: 1365-2567
Titre abrégé: Immunology
Pays: England
ID NLM: 0374672
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
29
08
2022
accepted:
24
10
2022
pubmed:
27
10
2022
medline:
25
3
2023
entrez:
26
10
2022
Statut:
ppublish
Résumé
Although the first cancer immunotherapy was given in the clinic more than a century ago, this line of treatment has remained more of a distant goal than a practical therapy due to limited understanding of the tumour microenvironment and the mechanisms at play within it, which led to failures of numerous clinical trials. However, in the last two decades, the immune checkpoint inhibitors (ICIs) and chimeric antigen receptor-T cell therapies have revolutionized the treatment of cancer and provided proof-of-concept that immunotherapies are a viable option. So far, immunotherapies have majoritarily focused on utilizing T cells; however, T cells are not autonomous but rather function as part of, and therefore are influenced by, a vast cast of other immune cells, including innate lymphoid cells (ILCs). Here, we summarize the role of ILCs, especially helper ILCs, in tumour development, progression and metastasis, as well as their potential to be used as immunotherapy for cancer. By reviewing the studies that used helper ILCs as adoptive cell therapy (ACT), we highlight the rationale behind considering these cells as novel ACT for cancer as well as identify open questions and areas for future research.
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
569-579Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):671-88. https://doi.org/10.1038/s41577-018-0061-z
Daher M, Rezvani K. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer. Cancer Discov. 2021;11(1):45-58. https://doi.org/10.1158/2159-8290.CD-20-0556
Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85-100. https://doi.org/10.1038/s41571-020-0426-7
Jacquelot N, Seillet C, Vivier E, Belz GT. Innate lymphoid cells and cancer. Nat Immunol. 2022;23(3):371-9. https://doi.org/10.1038/s41590-022-01127-z
Soriani A, Stabile H, Gismondi A, Santoni A, Bernardini G. Chemokine regulation of innate lymphoid cell tissue distribution and function. Cytokine Growth Factor Rev. 2018;42:47-55. https://doi.org/10.1016/j.cytogfr.2018.02.003
Karta MR, Rosenthal PS, Beppu A, Vuong CY, Miller M, Das S, et al. β2 integrins rather than β1 integrins mediate Alternaria-induced group 2 innate lymphoid cell trafficking to the lung. J Allergy Clin Immunol. 2018;141(1):329-338.e12. https://doi.org/10.1016/j.jaci.2017.03.010
Munneke JM, Björklund AT, Mjösberg JM, Garming-Legert K, Bernink JH, Blom B, et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood. 2014;124(5):812-21. https://doi.org/10.1182/blood-2013-11-536888
Kim CH, Hashimoto-Hill S, Kim M. Migration and tissue tropism of innate lymphoid cells. Trends Immunol. 2016;37(1):68-79. https://doi.org/10.1016/j.it.2015.11.003
Simoni Y, Fehlings M, Kløverpris HN, McGovern N, Koo SL, Loh CY, et al. Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency. Immunity. 2017;46(1):148-61. https://doi.org/10.1016/j.immuni.2016.11.005
Yudanin NA, Schmitz F, Flamar AL, Thome JJC, Tait Wojno E, Moeller JB, et al. Spatial and temporal mapping of human innate lymphoid cells reveals elements of tissue specificity. Immunity. 2019;50(2):505-519.e4. https://doi.org/10.1016/j.immuni.2019.01.012
Bal SM, Golebski K, Spits H. Plasticity of innate lymphoid cell subsets. Nat Rev Immunol. 2020;20(9):552-65. https://doi.org/10.1038/s41577-020-0282-9
Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174(5):1054-66. https://doi.org/10.1016/j.cell.2018.07.017
Gasteiger G, Fan X, Dikiy S, Lee SY, Rudensky AY. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science. 2015;350(6263):981-5. https://doi.org/10.1126/science.aac9593
Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517(7534):293-301. https://doi.org/10.1038/nature14189
Eberl G, Colonna M, Di Santo JP, McKenzie ANJ. Innate lymphoid cells: a new paradigm in immunology. Science. 2015;348(6237):aaa6566. https://doi.org/10.1126/science.aaa6566
Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13(2):145-9. https://doi.org/10.1038/nri3365
Everaere L, Ait Yahia S, Bouté M, Audousset C, Chenivesse C, Tsicopoulos A. Innate lymphoid cells at the interface between obesity and asthma. Immunology. 2018;153(1):21-30. https://doi.org/10.1111/imm.12832
Wang D, Bai S, Cui Y, Zhao N, Qi F, Liu J, et al. Respiratory syncytial virus prevents the subsequent development of ovalbumin-induced allergic responses by inhibiting ILC2 via the IL-33/ST2 pathway. Immunotherapy. 2018;10(12):1065-76. https://doi.org/10.2217/imt-2018-0059
López-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer Cell. 2017;32(2):135-54. https://doi.org/10.1016/j.ccell.2017.06.009
Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7-19. https://doi.org/10.1038/nrc.2015.5
Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769-81. https://doi.org/10.1016/j.ymthe.2017.06.012
Nabekura T, Shibuya A. Type 1 innate lymphoid cells: soldiers at the front line of immunity. Biom J. 2021;44(2):115-22. https://doi.org/10.1016/j.bj.2020.10.001
Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer. 1975;16(2):216-29. https://doi.org/10.1002/ijc.2910160204
Kiessling R, Klein E, Wigzell H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol. 1975;5(2):112-7. https://doi.org/10.1002/eji.1830050208
Lanier LL, Phillips JH, Hackett J, Tutt M, Kumar V. Natural killer cells: definition of a cell type rather than a function. J Immunol. 1986;137(9):2735-9.
Ducimetière L, Lucchiari G, Litscher G, Nater M, Heeb L, Nuñez NG, et al. Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis. Proc Natl Acad Sci USA. 2021;118(27):e2026271118. https://doi.org/10.1073/pnas.2026271118
Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017;18(9):1004-15. https://doi.org/10.1038/ni.3800
Dadi S, Chhangawala S, Whitlock BM, Franklin RA, Luo CT, Oh SA, et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell. 2016;164(3):365-77. https://doi.org/10.1016/j.cell.2016.01.002
Kansler ER, Dadi S, Krishna C, Nixon BG, Stamatiades EG, Liu M, et al. Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies. Nat Immunol. 2022;23(6):904-15. https://doi.org/10.1038/s41590-022-01213-2
Moreno-Nieves UY, Tay JK, Saumyaa S, Horowitz NB, Shin JH, Mohammad IA, et al. Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment. Proc Natl Acad Sci USA. 2021;118(28):e2101169118. https://doi.org/10.1073/pnas.2101169118
Qi J, Crinier A, Escalière B, Ye Y, Wang Z, Zhang T, et al. Single-cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression. Cell Rep Med. 2021;2(8):100353. https://doi.org/10.1016/j.xcrm.2021.100353
Li Z, Ma R, Ma S, Tian L, Lu T, Zhang J, et al. ILC1s control leukemia stem cell fate and limit development of AML. Nat Immunol. 2022;23(5):718-30. https://doi.org/10.1038/s41590-022-01198-y
Miyazono K, Katsuno Y, Koinuma D, Ehata S, Morikawa M. Intracellular and extracellular TGF-β signaling in cancer: some recent topics. Front Med. 2018;12(4):387-411. https://doi.org/10.1007/s11684-018-0646-8
Cortez VS, Ulland TK, Cervantes-Barragan L, Bando JK, Robinette ML, Wang Q, et al. SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling. Nat Immunol. 2017;18(9):995-1003. https://doi.org/10.1038/ni.3809
Bernink JH, Krabbendam L, Germar K, de Jong E, Gronke K, Kofoed-Nielsen M, et al. Interleukin-12 and -23 control plasticity of CD127+ group 1 and group 3 innate lymphoid cells in the intestinal lamina propria. Immunity. 2015;43(1):146-60. https://doi.org/10.1016/j.immuni.2015.06.019
Koh J, Kim HY, Lee Y, Park IK, Kang CH, Kim YT, et al. IL23-producing human lung cancer cells promote tumor growth via conversion of innate lymphoid cell 1 (ILC1) into ILC3. Clin Cancer Res. 2019;25(13):4026-37. https://doi.org/10.1158/1078-0432.CCR-18-3458
Kim J, Kim W, Moon UJ, Kim HJ, Choi HJ, Sin JI, et al. Intratumorally establishing type 2 innate lymphoid cells blocks tumor growth. J Immunol. 2016;196(5):2410-23. https://doi.org/10.4049/jimmunol.1501730
Huang Q, Jacquelot N, Preaudet A, Hediyeh-zadeh S, Souza-Fonseca-Guimaraes F, McKenzie ANJ, et al. Type 2 innate lymphoid cells protect against colorectal cancer progression and predict improved patient survival. Cancer. 2021;13(3):559. https://doi.org/10.3390/cancers13030559
Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol. 2012;188(2):703-13. https://doi.org/10.4049/jimmunol.1101270
Moral JA et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020;579(7797):130-5. https://doi.org/10.1038/s41586-020-2015-4
Nussbaum K, Burkhard SH, Ohs I, Mair F, Klose CSN, Arnold SJ, et al. Tissue microenvironment dictates the fate and tumorsuppressive function of type 3 ILCs. J Exp Med. 2017;214(8):2331-47. https://doi.org/10.1084/jem.20162031
Goc J, Lv M, Bessman NJ, Flamar AL, Sahota S, Suzuki H, et al. Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. Cell. 2021;184(19):5015-5030.e16. https://doi.org/10.1016/j.cell.2021.07.029
Carrega P, Loiacono F, di Carlo E, Scaramuccia A, Mora M, Conte R, et al. NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun. 2015;6(1):8280. https://doi.org/10.1038/ncomms9280
Salimi M, Wang R, Yao X, Li X, Wang X, Hu Y, et al. Activated innate lymphoid cell populations accumulate in human tumour tissues. BMC Cancer. 2018;18(1):341. https://doi.org/10.1186/s12885-018-4262-4
Bie Q, Zhang P, Su Z, Zheng D, Ying X, Wu Y, et al. Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer. J Immunol Res. 2014;2014:1-10. https://doi.org/10.1155/2014/923135
Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Investig. 2017;127(8):2916-29. https://doi.org/10.1172/JCI89717
Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017;8(1):593. https://doi.org/10.1038/s41467-017-00678-2
Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3-8. https://doi.org/10.1158/2326-6066.CIR-16-0297
Piranlioglu R, Lee EM, Ouzounova M, Bollag RJ, Vinyard AH, Arbab AS, et al. Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model. Nat Commun. 2019;10(1):1430. https://doi.org/10.1038/s41467-019-09015-1
Choi M-R, Sosman JA, Zhang B. The Janus face of IL-33 signaling in tumor development and immune escape. Cancer. 2021;13(13):3281. https://doi.org/10.3390/cancers13133281
Yeoh WJ, Vu VP, Krebs P. IL-33 biology in cancer: an update and future perspectives. Cytokine. 2022;157:155961. https://doi.org/10.1016/j.cyto.2022.155961
Xiao P, Wan X, Cui B, Liu Y, Qiu C, Rong J, et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology. 2016;5(1):e1063772. https://doi.org/10.1080/2162402X.2015.1063772
Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer. 2014;134(7):1669-82. https://doi.org/10.1002/ijc.28481
Long A, Dominguez D, Qin L, Chen S, Fan J, Zhang M, et al. Type 2 innate lymphoid cells impede IL-33-mediated tumor suppression. J Immunol. 2018;201(11):3456-64. https://doi.org/10.4049/jimmunol.1800173
Saadalla A, Lima MM, Tsai F, Osman A, Singh MP, Linden DR, et al. Cell intrinsic deregulated ß-catenin signaling promotes expansion of bone marrow derived connective tissue type mast cells, systemic inflammation, and colon cancer. Front Immunol. 2019;10:1-13. https://doi.org/10.3389/fimmu.2019.02777
Saadalla AM, Osman A, Gurish MF, Dennis KL, Blatner NR, Pezeshki A, et al. Mast cells promote small bowel cancer in a tumor stage-specific and cytokine-dependent manner. Proc Natl Acad Sci U S A. 2018;115(7):1588-92. https://doi.org/10.1073/pnas.1716804115
He Z, Chen L, Souto FO, Canasto-Chibuque C, Bongers G, Deshpande M, et al. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc min/+ mice. Sci Rep. 2017;7(1):1-14. https://doi.org/10.1038/s41598-017-05716-z
Mertz KD, Mager LF, Wasmer MH, Thiesler T, Koelzer VH, Ruzzante G, et al. The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. OncoImmunology. 2016;5(1):1-11. https://doi.org/10.1080/2162402X.2015.1062966
Busser B, Sancey L, Brambilla E, Coll J-L, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011;1816(2):119-31. https://doi.org/10.1016/j.bbcan.2011.05.003
Zaiss DMW, Gause WC, Osborne LC, Artis D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity. 2015;42(2):216-26. https://doi.org/10.1016/j.immuni.2015.01.020
Drake LY, Kita H. Group 2 innate lymphoid cells in the lung. 2014;124:1-16. https://doi.org/10.1016/B978-0-12-800147-9.00001-7
Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-33-responsive lineage-CD25+ CD44 hi lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol. 2012;188(3):1503-13. https://doi.org/10.4049/jimmunol.1102832
Halim TYF, Krauß RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity. 2012;36(3):451-63. https://doi.org/10.1016/j.immuni.2011.12.020
Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CGK, Doering TA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol. 2011;12(11):1045-54. https://doi.org/10.1038/ni.2131
Shen C, Liu C, Zhang Z, Ping Y, Shao J, Tian Y, et al. PD-1 affects the immunosuppressive function of group 2 innate lymphoid cells in human non-small cell lung cancer. Front Immunol. 2021;12:680055. https://doi.org/10.3389/fimmu.2021.680055
Melo-Gonzalez F, Hepworth MR. Functional and phenotypic heterogeneity of group 3 innate lymphoid cells. Immunology. 2017;150(3):265-75. https://doi.org/10.1111/imm.12697
Crome SQ, Nguyen LT, Lopez-Verges S, Yang SYC, Martin B, Yam JY, et al. A distinct innate lymphoid cell population regulates tumor-associated T cells. Nat Med. 2017;23(3):368-75. https://doi.org/10.1038/nm.4278
Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013;210(5):917-31. https://doi.org/10.1084/jem.20122308
Irshad S, Flores-Borja F, Lawler K, Monypenny J, Evans R, Male V, et al. RORγt+ innate lymphoid cells promote lymph node metastasis of breast cancers. Cancer Res. 2017;77(5):1083-96. https://doi.org/10.1158/0008-5472.CAN-16-0598
Chan IH, Jain R, Tessmer MS, Gorman D, Mangadu R, Sathe M, et al. Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells. Mucosal Immunol. 2014;7(4):842-56. https://doi.org/10.1038/mi.2013.101
Xuan X, Zhou J, Tian Z, Lin Y, Song J, Ruan Z, et al. ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling. Clin Transl Oncol. 2020;22(4):563-75. https://doi.org/10.1007/s12094-019-02160-5
Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307-25. https://doi.org/10.1038/s41568-019-0144-6
Liu J, Xiao C, Wang H, Xue Y, Dong D, Lin C, et al. Local group 2 innate lymphoid cells promote corneal regeneration after epithelial abrasion. Am J Pathol. 2017;187(6):1313-26. https://doi.org/10.1016/j.ajpath.2017.02.010
Omata Y, Frech M, Primbs T, Lucas S, Andreev D, Scholtysek C, et al. Group 2 innate lymphoid cells attenuate inflammatory arthritis and protect from bone destruction in mice. Cell Rep. 2018;24(1):169-80. https://doi.org/10.1016/j.celrep.2018.06.005
He Y, Xu H, Song C, Koprivsek JJ, Arulanandam B, Yang H, et al. Adoptive transfer of group 3-like innate lymphoid cells restores mouse colon resistance to colonization of a gamma interferon-susceptible chlamydia muridarum mutant. Infect Immun. 2021;89(2):1-12. https://doi.org/10.1128/IAI.00533-20
Mirchandani AS, Besnard AG, Yip E, Scott C, Bain CC, Cerovic V, et al. Type 2 innate lymphoid cells drive CD4 + Th2 cell responses. J Immunol. 2014;192(5):2442-8. https://doi.org/10.4049/jimmunol.1300974
Patel DF, Peiró T, Bruno N, Vuononvirta J, Akthar S, Puttur F, et al. Neutrophils restrain allergic airway inflammation by limiting ILC2 function and monocyte-dendritic cell antigen presentation. Sci Immunol. 2019;4(41):eaax7006. https://doi.org/10.1126/sciimmunol.aax7006
Taylor S, Huang Y, Mallett G, Stathopoulou C, Felizardo TC, Sun MA, et al. PD-1 regulates KLRG1+ group 2 innate lymphoid cells. J Exp Med. 2017;214(6):1663-78. https://doi.org/10.1084/jem.20161653
Frech M et al. An in vivo gene delivery approach for the isolation of reasonable numbers of type 2 innate lymphoid cells. MethodsX. 2020;7:101054. https://doi.org/10.1016/j.mex.2020.101054
Guo X, Muite K, Wroblewska J, Fu Y-X. Purification and adoptive transfer of group 3 gut innate lymphoid cells. Methods Mol Biol. 2016;1422:189-96. https://doi.org/10.1007/978-1-4939-3603-8_18
de Lucía Finkel P, Sherwood C, Saranchova I, Xia W, Munro L, Pfeifer CG, et al. Serum free culture for the expansion and study of type 2 innate lymphoid cells. Sci Rep. 2021;11(1):12233. https://doi.org/10.1038/s41598-021-91500-z
Calvi M, di Vito C, Frigo A, Trabanelli S, Jandus C, Mavilio D. Development of human ILCs and impact of unconventional cytotoxic subsets in the pathophysiology of inflammatory diseases and cancer. Front Immunol. 2022;13:1-13. https://doi.org/10.3389/fimmu.2022.914266
Lim AI, Di Santo JP. ILC-poiesis: ensuring tissue ILC differentiation at the right place and time. Eur J Immunol. 2019;49(1):11-8. https://doi.org/10.1002/eji.201747294
Tang Q, Ahn YO, Southern P, Blazar BR, Miller JS, Verneris MR. Development of IL-22-producing NK lineage cells from umbilical cord blood hematopoietic stem cells in the absence of secondary lymphoid tissue. Blood. 2011;117(15):4052-5. https://doi.org/10.1182/blood-2010-09-303081
Tufa DM, Yingst AM, Trahan GD, Shank T, Jones D, Shim S, et al. Human innate lymphoid cell precursors express CD48 that modulates ILC differentiation through 2B4 signaling. Sci Immunol. 2020;5(53):eaay4218. https://doi.org/10.1126/sciimmunol.aay4218
Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, et al. Systemic human ILC precursors provide a substrate for tissue ILC differentiation. Cell. 2017;168(6):1086-1100.e10. https://doi.org/10.1016/j.cell.2017.02.021
Xing Y, Stefanski H, Bruce DW, Hippen KL, Coghill JM Jr, McKinnon K, et al. A novel process for the expansion of functional human ILC2 cells for Gvhd prevention. Blood. 2017;130:4432. https://doi.org/10.1182/blood.V130.Suppl_1.4432.4432
Fix SM, Jazaeri AA, Hwu P. Applications of crispr genome editing to advance the next generation of adoptive cell therapies for cancer. Cancer Discov. 2021;11(3):560-74. https://doi.org/10.1158/2159-8290.CD-20-1083
Marcus A, Eshhar Z. Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer. Oncotarget. 2011;2(7):525-6. https://doi.org/10.18632/oncotarget.300
Dogan M, Karhan E, Kozhaya L, Placek L, Chen X, Yigit M, et al. Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy. J Immunol. 2022;209:1523-31. https://doi.org/10.4049/jimmunol.2100856
Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254-67. https://doi.org/10.1038/s41571-022-00600-w
Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6-15. https://doi.org/10.1038/s41416-018-0328-y
Crinier A, Vivier E, Bléry M. Helper-like innate lymphoid cells and cancer immunotherapy. Semin Immunol. 2019;41(January):101274. https://doi.org/10.1016/j.smim.2019.04.002
Bordon Y. Neuroimmunology: ILC2s touch a nerve. Nat Rev Immunol. 2017;17(11):661. https://doi.org/10.1038/nri.2017.119